Core Viewpoint - Artivion (AORT) reported quarterly earnings of $0.17 per share, exceeding the Zacks Consensus Estimate of $0.14 per share, compared to break-even earnings per share a year ago, indicating a positive earnings surprise of +21.43% [1] Financial Performance - The company posted revenues of $115.99 million for the quarter ended December 2025, which missed the Zacks Consensus Estimate by 1.07%, but showed an increase from year-ago revenues of $97.31 million [2] - Over the last four quarters, Artivion has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Performance - Artivion shares have declined approximately 12.1% since the beginning of the year, while the S&P 500 has gained 1.4% [3] - The current Zacks Rank for Artivion is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.06 on revenues of $114.9 million, and for the current fiscal year, it is $0.66 on revenues of $492.45 million [7] - The estimate revisions trend for Artivion was mixed ahead of the earnings release, which could change following the recent report [6] Industry Context - The Medical - Instruments industry, to which Artivion belongs, is currently in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8]